News

Ophthalmology Times

Kalaris enrolling phase 1b/2 study of TH103 for nAMD

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and ...
The Brighterside of News on MSN

Breakthrough AI-tool predicts risk of dementia from retinal eye scans

Dementia has become one of the world’s most pressing health challenges. Millions of people live with the condition, and the ...